DNA methylation at selected CpG sites in peripheral blood leukocytes is predictive of gastric cancer

Anticancer Research

Volumn 34, Issue 10, 2014, Pages 5381-5388

  Dauksa, Albertas ^a   Gulbinas, Antanas ^a   Endzinas, Zilvinas ^a   Oldenburg, Johannes ^b   El Maarri, Osman ^b  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

DNA methylation; Gastric cancer; Peripheral blood leukocyte; SIRPH.; Surrogate tissue

Indexed keywords

REPETITIVE DNA;

ACIN1 GENE; ADULT; AGED; ALU SEQUENCE; APC GENE; ARTICLE; BCL2 GENE; CANCER PATIENT; CASE CONTROL STUDY; CD44 GENE; CDKN2A GENE; CELL DIFFERENTIATION; CONTROLLED STUDY; CPG ISLAND; DAPK1 GENE; DISEASE SEVERITY; DISTANT METASTASIS; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE; LINE 1 GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PREDICTION; PROMOTER REGION; RARB GENE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STOMACH CANCER; TNFRSF10C HS3ST2 GENE; TUMOR SUPPRESSOR GENE; CANCER GRADING; CANCER STAGING; CLUSTER ANALYSIS; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; NUCLEOTIDE REPEAT; PATHOLOGY; PREVALENCE; STOMACH NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PREVALENCE; REPETITIVE SEQUENCES, NUCLEIC ACID; STOMACH NEOPLASMS;

EID: 84917708856     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M and Nakayama H: Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8: 86-94, 2005.
3. Yokozaki H, Yasui W and Tahara E: Genetic and epigenetic changes in stomach cancer. Int Rev Cytol 204: 49-95, 2001.
4. Ushijima T and Sasako M: Focus on gastric cancer. Cancer Cell 5: 121-125, 2004.
5. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
6. McKay JA, Xie L, Harris S, Wong YK, Ford D and Mathers JC: Blood as a surrogate marker for tissue-specific DNA methylation and changes due to folate depletion in post-partum female mice. Mol Nutr Food Res 55: 1026-1035, 2011.
7. Christensen BC, Houseman EA, Marsit CJ, Zheng S, Wrensch MR, Wiemels JL, Nelson HH, Karagas MR, Padbury JF, Bueno R, Sugarbaker DJ, Yeh RF, Wiencke JK and Kelsey KT: Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 5: e1000602, 2009.
8. Kile ML, Baccarelli A, Tarantini L, Hoffman E, Wright RO and Christiani DC: Correlation of global and gene-specific DNA methylation in maternal-infant pairs. PLoS One 5: e13730, 2010.
9. Gao Y, Baccarelli A, Shu XO, Ji BT, Yu K, Tarantini L, Yang G, Li HL, Hou L, Rothman N, Zheng W, Gao YT and Chow WH: Blood leukocyte Alu and LINE-1 methylation and gastric cancer risk in the Shanghai Women's Health Study. Br J Cancer 106: 585-591, 2012.
10. Hou L, Wang H, Sartori S, Gawron A, Lissowska J, Bollati V, Tarantini L, Zhang FF, Zatonski W, Chow WH and Baccarelli A: Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. Int J Cancer 127: 1866-1874, 2010.
11. Lim U, Flood A, Choi SW, Albanes D, Cross AJ, Schatzkin A, Sinha R, Katki HA, Cash B, Schoenfeld P and Stolzenberg-Solomon R: Genomic methylation of leukocyte DNA in relation to colorectal adenoma among asymptomatic women. Gastroenterology 134: 47-55, 2008.
12. Pufulete M, Al-Ghnaniem R, Leather AJ, Appleby P, Gout S, Terry C, Emery PW and Sanders TA: Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology 124: 1240-1248, 2003.
13. Choi JY, James SR, Link PA, McCann SE, Hong CC, Davis W, Nesline MK, Ambrosone CB and Karpf AR: Association between global DNA hypomethylation in leukocytes and risk of breast cancer. Carcinogenesis 30: 1889-1897, 2009.
14. Cash HL, Tao L, Yuan JM, Marsit CJ, Houseman EA, Xiang YB, Gao YT, Nelson HH and Kelsey KT: LINE-1 hypomethylation is associated with bladder cancer risk among nonsmoking Chinese. Int J Cancer 130: 1151-1159, 2012.
15. Moore LE, Pfeiffer RM, Poscablo C, Real FX, Kogevinas M, Silverman D, Garcia-Closas R, Chanock S, Tardon A, Serra C, Carrato A, Dosemeci M, Garcia-Closas M, Esteller M, Fraga M, Rothman N and Malats N: Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol 9: 359-366, 2008.
16. Wilhelm CS, Kelsey KT, Butler R, Plaza S, Gagne L, Zens MS, Andrew AS, Morris S, Nelson HH, Schned AR, Karagas MR and Marsit CJ: Implications of LINE1 methylation for bladder cancer risk in women. Clin Cancer Res 16: 1682-1689, 2010.
17. Hsiung DT, Marsit CJ, Houseman EA, Eddy K, Furniss CS, McClean MD and Kelsey KT: Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 16: 108-114, 2007.
18. Liao LM, Brennan P, van Bemmel DM, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Rothman N, Boffetta P, Chow WH and Moore LE: LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer. PLoS One 6: e27361, 2011.
19. Dauksa A, Gulbinas A, Barauskas G, Pundzius J, Oldenburg J and El-Maarri O: Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot study. PLoS One 7: e37509, 2012.
20. Flanagan JM, Munoz-Alegre M, Henderson S, Tang T, Sun P, Johnson N, Fletcher O, Dos SS, I, Peto J, Boshoff C, Narod S and Petronis A: Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet 18: 1332-1342, 2009.
21. Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y and Noguchi S: BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat 129: 69-77, 2011.
22. Kaaks R, Stattin P, Villar S, Poetsch AR, Dossus L, Nieters A, Riboli E, Palmqvist R, Hallmans G, Plass C and Friesen MD: Insulin-like growth factor-II methylation status in lymphocyte DNA and colon cancer risk in the Northern Sweden Health and Disease cohort. Cancer Res 69: 5400-5405, 2009.
23. Pedersen KS, Bamlet WR, Oberg AL, de AM, Matsumoto ME, Tang H, Thibodeau SN, Petersen GM and Wang L: Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS One 6: e18223, 2011.
24. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ and Brenner H: Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One 3: e2656, 2008.
25. Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, Giles GG, Hopper JL and Dobrovic A: Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) 4: 23-33, 2011.
26. Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB and Gazdar AF: Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 247: 56-71, 2007.
27. Liggett WH, Jr. and Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197-1206, 1998.
28. Deng G, Song GA, Pong E, Sleisenger M and Kim YS: Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor. Cancer Res 64: 2692-2698, 2004.
29. Bernal C, Aguayo F, Villarroel C, Vargas M, Diaz I, Ossandon FJ, Santibanez E, Palma M, Aravena E, Barrientos C and Corvalan AH: Reprimo as a potential biomarker for early detection in gastric cancer. Clin Cancer Res 14: 6264-6269, 2008.
30. Miyamoto K, Asada K, Fukutomi T, Okochi E, Yagi Y, Hasegawa T, Asahara T, Sugimura T and Ushijima T: Methylationassociated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene 22: 274-280, 2003.
31. Widschwendter M, Berger J, Muller HM, Zeimet AG and Marth C: Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J Mammary Gland Biol Neoplasia 6: 193-201, 2001.
32. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D and Kang GH: Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 211: 269-277, 2007.
33. Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, Yigit N, Hoyoux C, Laureys G, De PA, Speleman F and Vandesompele J: Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett 273: 336-346, 2009.
34. Shu Y, Iijima T, Sun W, Kano J, Ishiyama T, Okubo C, Anami Y, Tanaka R, Fukai S and Noguchi M: The ACIN1 gene is hypermethylated in early stage lung adenocarcinoma. J Thorac Oncol 1: 160-167, 2006.
35. Kito H, Suzuki H, Ichikawa T, Sekita N, Kamiya N, Akakura K, Igarashi T, Nakayama T, Watanabe M, Harigaya K and Ito H: Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate 49: 110-115, 2001.
36. Kwon SJ: Evaluation of the 7th UICC TNM Staging System of Gastric Cancer. J Gastric Cancer 11: 78-85, 2011.
37. El-Maarri O: SIRPH analysis: SNuPE with IP-RP-HPLC for quantitative measurements of DNA methylation at specific CpG sites. Methods Mol Biol 287: 195-205, 2004.
38. El-Maarri O, Herbiniaux U, Walter J and Oldenburg J: A rapid, quantitative, non-radioactive bisulfite-SNuPE- IP RP HPLC assay for methylation analysis at specific CpG sites. Nucleic Acids Res 30: e25, 2002.
39. Wang L, Aakre JA, Jiang R, Marks RS, Wu Y, Chen J, Thibodeau SN, Pankratz VS and Yang P: Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA. J Thorac Oncol 5: 778-785, 2010.
40. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR and Feinberg AP: Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299: 1753-1755, 2003.
41. Chan AW, Chan MW, Lee TL, Ng EK, Leung WK, Lau JY, Tong JH, Chan FK and To KF: Promoter hypermethylation of Deathassociated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 13: 937-941, 2005.
42. Oue N, Motoshita J, Yokozaki H, Hayashi K, Tahara E, Taniyama K, Matsusaki K and Yasui W: Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol 198: 55-59, 2002.
43. Sarbia M, Geddert H, Klump B, Kiel S, Iskender E and Gabbert HE: Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer 111: 224-228, 2004.
44. Shutoh M, Oue N, Aung PP, Noguchi T, Kuraoka K, Nakayama H, Kawahara K and Yasui W: DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation. Cancer 104: 1609-1619, 2005.
45. Ben Ayed-Guerfali D, Benhaj K, Khabir A, Abid M, Bayrouti MI, Sellami-Boudawara T, Gargouri A and Mokdad-Gargouri R: Hypermethylation of tumor-related genes in Tunisian patients with gastric carcinoma: clinical and biological significance. J Surg Oncol 103: 687-694, 2011.
46. Motoshita J, Oue N, Nakayama H, Kuraoka K, Aung PP, Taniyama K, Matsusaki K and Yasui W: DNA methylation profiles of differentiated-type gastric carcinomas with distinct mucin phenotypes. Cancer Sci 96: 474-479, 2005.
47. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904, 2004.